The Chemours Company (NYSE:CC) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• The Chemours Company (NYSE:CC) has an average analyst recommendation of "Hold," with two sell, three hold, and five buy ratings amid a price target range from $18 to $21.
• Shares of Chemours opened at $14.06, with a market capitalization of $2.11 billion and a price-to-earnings ratio of -5.02.
• The company recently cut its dividend, announcing a quarterly payment of $0.0875 per share, translating to an annualized yield of 2.5%.

The Chemours Company (NYSE:CC - Get Free Report) has earned an average recommendation of "Hold" from the ten brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $18.50.

A number of analysts recently weighed in on CC shares. Mizuho decreased their price objective on Chemours from $19.00 to $18.00 and set an "outperform" rating for the company in a report on Thursday, October 16th. UBS Group increased their price target on Chemours from $17.00 to $21.00 and gave the company a "buy" rating in a research note on Monday, October 6th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Chemours in a research note on Friday. Truist Financial upped their target price on Chemours from $18.00 to $21.00 and gave the company a "buy" rating in a report on Tuesday, September 16th. Finally, Zacks Research lowered shares of Chemours from a "hold" rating to a "strong sell" rating in a report on Friday, October 17th.

Chemours Stock Performance

Shares of CC stock opened at $14.06 on Friday. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -5.02 and a beta of 1.65. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16. The business's 50-day moving average price is $15.30 and its 200-day moving average price is $13.09. Chemours has a 12 month low of $9.13 and a 12 month high of $22.38.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The business had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the company earned $0.38 EPS. The firm's revenue was up 5.0% compared to the same quarter last year. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that Chemours will post 2.03 EPS for the current year.

Chemours Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were paid a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Friday, August 15th. Chemours's dividend payout ratio (DPR) is currently -12.50%.

Insider Buying and Selling

In other Chemours news, CEO Denise Dignam purchased 4,068 shares of the business's stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the acquisition, the chief executive officer owned 191,546 shares of the company's stock, valued at approximately $2,310,044.76. This represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.47% of the company's stock.

Institutional Investors Weigh In On Chemours

Large investors have recently bought and sold shares of the stock. MTM Investment Management LLC acquired a new position in shares of Chemours during the second quarter valued at about $27,000. SouthState Corp bought a new stake in Chemours in the 1st quarter valued at about $34,000. GAMMA Investing LLC raised its stake in Chemours by 130.7% during the 2nd quarter. GAMMA Investing LLC now owns 3,175 shares of the specialty chemicals company's stock worth $36,000 after buying an additional 1,799 shares during the period. Evelyn Partners Asset Management Ltd bought a new position in Chemours in the second quarter worth approximately $37,000. Finally, FNY Investment Advisers LLC grew its stake in Chemours by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 4,000 shares of the specialty chemicals company's stock valued at $45,000 after acquiring an additional 2,000 shares during the period. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.